Before propensity score matching | After propensity score matching | Â | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cohort |  | Patients | Mean ± SD | P-Value | Std diff. | Mean ± SD | Patients | P-Value | Std diff. | ||
1 | AI | Age at Index | 167 | 64.5 +/- 11.6 | 0.126 | 0.137 | 64.5 +/- 11.6 | 167 | 100% | 0.323 | |
2 | Â | Â | 180,586 | 62.6 +/- 16.5 | Â | Â | 65.8 +/- 11.8 | 167 | 100% | Â | |
Cohort | Â | Patients | % of Cohort | P-Value | Std diff. | Patients | % of Cohort | P-Value | Std diff. | ||
1 | 2106-3 | White | 126 | 75.4% | <0.001 | 0.288 | 126 | 75.4% | 0.024 | 0.250 | |
2 | Â | Â | 117,798 | 62.2% | Â | Â | 107 | 64.1% | Â | Â | |
1 | 2054-5 | Black or African | 18 | 10.8% | 0.132 | 0.124 | 18 | 10.8% | 0.011 | 0.281 | |
2 | Â | American | 28,266 | 14.9% | Â | Â | 35 | 21.0% | Â | Â | |
1 | M | Male | 99 | 59.3% | 0.073 | 0.140 | 99 | 59.3% | 1 | <0.001 | |
2 | Â | Â | 99,085 | 52.3% | Â | Â | 99 | 59.3% | Â | Â | |
1 | F | Female | 64 | 38.3% | 0.198 | 0.101 | 64 | 38.3% | 1 | <0.001 | |
2 | Â | Â | 81,886 | 43.3% | Â | Â | 64 | 38.3% | Â | Â | |
1 | 2028-9 | Asian | 10 | 6.0% | 0.100 | 0.111 | 10 | 6.0% | 1 | <0.001 | |
2 | Â | Â | 6,835 | 3.6% | Â | Â | 10 | 6.0% | Â | Â | |
1 | 2131-1 | Other Race | 10 | 6.0% | 0.129 | 0.104 | 10 | 6.0% | 1 | <0.001 | |
2 | Â | Â | 7,106 | 3.8% | Â | Â | 10 | 6.0% | Â | Â | |
Cohort | Â | Patients | % of Cohort | P-Value | Std diff. | Patients | % of Cohort | P-Value | Std diff. | ||
1 | I20-I25 | Ischemic heart | 49 | 29.3% | 0.003 | 0.215 | 49 | 29.3% | 1 | <0.001 | |
2 | Â | diseases | 38,072 | 20.1% | Â | Â | 49 | 29.3% | Â | Â | |
1 | E08-E13 | Diabetes mellitus | 46 | 27.5% | 0.849 | 0.015 | 46 | 27.5% | 1 | <0.001 | |
2 | Â | Â | 50,899 | 26.9% | Â | Â | 46 | 27.5% | Â | Â | |
1 | E40-E46 | Malnutrition | 11 | 6.6% | 0.141 | 0.102 | 11 | 6.6% | 0.822 | 0.025 | |
2 | Â | Â | 8,104 | 4.3% | Â | Â | 10 | 6.0% | Â | Â | |
1 | C34 | Malignant neoplasm of bronchus and lung | 10 | 6.0% | <0.001 | 0.259 | 10 | 6.0% | 1 | <0.001 | |
2 | Â | Â | 2,272 | 1.2% | Â | Â | 10 | 6.0% | Â | Â | |
1 | Z87.891 | Personal history of nicotine dependence | 39 | 23.4% | 0.003 | 0.210 | 39 | 23.4% | 0.282 | 0.118 | |
2 | Â | Â | 28,627 | 15.1% | Â | Â | 31 | 18.6% | Â | Â | |
1 | Z72.0 | Tobacco use | 10 | 6.0% | 0.059 | 0.125 | 10 | 6.0% | 1 | <0.001 | |
2 | Â | Â | 6,347 | 3.4% | Â | Â | 10 | 6.0% | Â | Â | |
1 | K70 | Alcoholic liver | 10 | 6.0% | <0.001 | 0.286 | 10 | 6.0% | 1 | <0.001 | |
2 | Â | disease | 1,597 | 0.8% | Â | Â | 10 | 6.0% | Â | Â | |
Cohort | Â | Patients | % of Cohort | P-Value | Std diff. | Patients | % of Cohort | P-Value | Std diff. | ||
1 | HS050 | ADRENAL | 114 | 68.3% | <0.001 | 0.393 | 114 | 68.3% | 1 | <0.001 | |
2 | Â | CORTICOSTEROIDS | 93,286 | 49.3% | Â | Â | 114 | 68.3% | Â | Â | |
1 | 3264 | dexamethasone | 61 | 36.5% | 0.015 | 0.181 | 61 | 36.5% | 0.219 | 0.135 | |
2 | Â | Â | 53,188 | 28.1% | Â | Â | 72 | 43.1% | Â | Â | |
1 | 6902 | methylprednisolone | 61 | 36.5% | <0.001 | 0.288 | 61 | 36.5% | 0.246 | 0.127 | |
2 | Â | Â | 44,376 | 23.4% | Â | Â | 51 | 30.5% | Â | Â | |
1 | 5492 | hydrocortisone | 17 | 10.2% | 0.680 | 0.031 | 17 | 10.2% | 0.312 | 0.111 | |
2 | Â | Â | 17,517 | 9.3% | Â | Â | 23 | 13.8% | Â | Â | |
1 | 8640 | prednisone | 62 | 37.1% | <0.001 | 0.382 | 62 | 37.1% | 0.164 | 0.153 | |
2 | Â | Â | 38,179 | 20.2% | Â | Â | 50 | 29.9% | Â | Â | |
1 | 2,284,718 | remdesivir | 10 | 6.0% | 0.592 | 0.040 | 10 | 6.0% | 1 | <0.001 | |
2 | Â | Â | 9,611 | 5.1% | Â | Â | 10 | 6.0% | Â | Â | |
1 | 612,865 | tocilizumab | 10 | 6.0% | <0.001 | 0.322 | 10 | 6.0% | 0.001 | 0.357 | |
2 | Â | Â | 760 | 0.4% | Â | Â | 0 | 0% | Â | Â | |
1 | 2,047,232 | baricitinib | 10 | 6.0% | <0.001 | 0.318 | 10 | 6.0% | 1 | <0.001 | |
2 | Â | Â | 843 | 0.4% | Â | Â | 10 | 6.0% | Â | Â |